Insights on the Bioavailability Enhancement Technologies and Services Global Market to 2035 – Industry Trends and Forecasts – Yahoo Finance

Dublin, Dec. 12, 2022 (GLOBE NEWSWIRE) — The “Bioavailability Enhancement Technologies and Services Market by Drug Class, BCS Classification, Bioavailability Enhancement Approach, Dosage Form and Key Geographies: Industry Trends and Global Forecasts, 2022-2035” report has been added to ResearchAndMarkets.com’s offering.
This report features an extensive study of the current market landscape and future potential of the bioavailability enhancement technologies and services market. The study features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in providing bioavailability enhancement technologies and services. Amongst other elements, the report features:
Bioavailability is known to form an integral part of the drug pharmacokinetics. As a result, over the last couple of years, the concept of bioavailability has garnered significant attention in the pharmaceutical industry. Further, a study conducted on terminated drug development projects revealed that majority of the candidates fail in early phases.
The study further highlighted that the aforementioned drug failures can primarily be attributed to the problems associated with pharmacokinetic profiles, ADME (distribution, metabolism, absorption and excretion) properties and toxicity-related concerns. At present, more than 40% of the marketed drugs are believed to possess low bioavailability, while around 90% of all New Chemical Entities (NCEs), which are being evaluated in pre-clinical and clinical stages of development, exhibit solubility / permeability related issues.
Consequently, recent years have seen a rise in drug developers evaluating various re-formulation strategies to improve the bioavailability of existing drugs / drug candidates. In fact, an increasing number of drug candidates have been granted approval via the 505(b)(2) pathway; the aforementioned pathway is used to gain approval for novel formulations consisting of previously approved active pharmaceutical ingredient (API). Additionally, given the shifting focus of drug developers towards development of lipophilic drug compounds, the industry is actively undertaking efforts to identify various bioavailability enhancement techniques, in order to mitigate the challenge of low bioavailability and stability.
In this context, it is also important to mention that a significant number of players engaged in the development of therapeutic interventions currently prefer to outsource their bioavailability enhancement operations to contract service providers. This trend can be attributed to the fact that service providers usually have specialized facilities and equipment, along with established processes, which can help drug developers to accomplish the desired goals in shorter timelines.
In order to cater to the requirement for such services, a number of bioavailability enhancement focused service providers for API have been established in the past few years, across various regions of the globe. At present, the bioavailability enhancement service providers are actively trying to consolidate their presence in this field by entering into strategic alliances, to meet the indubitably rising demand for effective therapeutics.
For this purpose, substantial mergers and acquisitions have been reported in this market, as service providers strive to become one-stop-shops, to cater to the diverse needs for their clientele. In addition, several stakeholders are engaged in the development of proprietary technologies, based on sustained release principle and bioavailability enhancers, to maintain a competitive edge in this rapidly emerging market.
In fact, since 2017, close to 6,000 research articles, evaluating various bioavailability enhancement techniques have been published across several reputed journals. In addition, close to 10,000 patents have been filed, till 2022, providing a significant scientific push for the development of novel approaches. Driven by the increase in number of BCS II and BCS IV molecules being evaluated in early phases of development, the bioavailability enhancement domain is expected to grow at a steady pace in the foreseen future.
Frequently Asked Questions
Who are the key players engaged in the bioavailability enhancement technologies and services market?
Which are the key geographies where bioavailability enhancement technology and service providers are located?
What are the recent developments and expected trends in the bioavailability enhancement industry?
Which partnership models are commonly adopted by stakeholders offering bioavailability enhancement solutions?
What is the evolving trend of publications focused on bioavailability enhancement technologies?
Which companies are actively filing patents to drive innovation in the bioavailability enhancement market?
What are the key market trends and driving factors that are likely to impact the growth of the bioavailability enhancement technologies and services market?
How is the current and future opportunity likely to be distributed across key market segment?
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT SERVICE PROVIDERS
4.1. Chapter Overview
4.2. Bioavailability Enhancement Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Bioavailability Enhancement Principle
4.2.5. Analysis by Bioavailability Enhancement Approach
4.2.5.1. Analysis by Solid Dispersion Approaches
4.2.5.2. Analysis by Size Reduction Approaches
4.2.5.3. Analysis by Lipid-Based Approaches
4.2.5.4. Analysis by Other Bioavailability Enhancement Approaches
4.2.6. Analysis by Dosage Form
4.2.7. Analysis by Route of Administration
5. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT TECHNOLOGY PROVIDERS
5.1. Chapter Overview
5.2. Bioavailability Enhancement Technologies: Technology Providers Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Company Size and Location of Headquarters
5.2.5. Leading Players: Analysis by Number of Technologies
5.3. Bioavailability Enhancement Technologies: Market Landscape
5.3.1. Analysis by Bioavailability Enhancement Principle
5.3.2. Analysis by Bioavailability Enhancement Approach
5.3.3. Analysis by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
5.3.4. Analysis by Type of Molecule
5.3.5. Analysis by Bioavailability Enhancement Approach and Type of Molecule
5.3.6. Analysis by Dosage Form
5.3.7. Analysis by Route of Administration
5.3.8. Analysis by Availability for License
5.3.9. Analysis by Intellectual Property Rights
6. KEY INSIGHTS
6.1. Chapter Overview
6.1.1. Analysis by Company Size and Location of Headquarters (World Map Representation)
6.1.2. Analysis by Location of Headquarters and Bioavailability Enhancement Approach (Waffle Chart)
6.1.3. Analysis by Bioavailability Enhancement Approach and Dosage Form (Heatmap Representation)
6.1.4. Analysis by Company Size and Bioavailability Enhancement Principle (Horizontally Grouped Bar Chart)
6.1.5. Analysis by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach (Tree map Representation)
6.1.6. Analysis by Year of Establishment, Company Size, Number of Bioavailability Enhancement Approaches Offered and Region (3D Bubble Chart)
7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Adare Pharma Solutions
7.2.1. Company Overview
7.2.2. Financial Overview
7.2.3. Bioavailability Enhancement Services Portfolio
7.2.4. Recent Developments and Future Outlook
7.3. Ascendia Pharmaceuticals
7.3.1. Company Overview
7.3.2. Financial Overview
7.3.3. Bioavailability Enhancement Services Portfolio
7.3.4. Recent Developments and Future Outlook
7.4. Catalent
7.4.1. Company Overview
7.4.2. Financial Overview
7.4.3. Bioavailability Enhancement Services Portfolio
7.4.4. Recent Developments and Future Outlook
7.5. Formulex Pharma Innovations (formerly SoluBest)
7.5.1. Company Overview
7.5.2. Financial Overview
7.5.3. Bioavailability Enhancement Services Portfolio
7.5.4. Recent Developments and Future Outlook
7.6. Lonza
7.6.1. Company Overview
7.6.2. Financial Overview
7.6.3. Bioavailability Enhancement Services Portfolio
7.6.4. Recent Developments and Future Outlook
7.7. Lubrizol Life Science Health
7.7.1. Company Overview
7.7.2. Financial Overview
7.7.3. Bioavailability Enhancement Services Portfolio
7.7.4. Recent Developments and Future Outlook
7.8. Pace Analytical
7.8.1. Company Overview
7.8.2. Financial Overview
7.8.3. Bioavailability Enhancement Services Portfolio
7.8.4. Recent Developments and Future Outlook
7.9. Quotient Sciences
7.9.1. Company Overview
7.9.2. Financial Overview
7.9.3. Bioavailability Enhancement Services Portfolio
7.9.4. Recent Developments and Future Outlook
7.10. WuXi STA (A Subsidiary of WuXi AppTec)
7.10.1. Company Overview
7.10.2. Financial Overview
7.10.3. Bioavailability Enhancement Services Portfolio
7.10.4. Recent Developments and Future Outlook
8. COMPANY BENCHMARK ANALYSIS
8.1. Chapter Overview
8.2. Company Benchmarking Analysis: Methodology
8.3. Company Benchmarking Analysis: Peer Groups
8.3.1. Benchmarking of Players based in North America, Established Pre 2000 (Peer Group I)
8.3.2. Benchmarking of Players based in North America, Established 2000-2010 (Peer Group II)
8.3.3. Benchmarking of Players based in North America, Established Post 2010 (Peer Group III)
8.3.4. Benchmarking of Players based in Europe, Established Pre 2000 (Peer Group IV)
8.3.5. Benchmarking of Players based in Europe, Established 2000-2010 (Peer Group V)
8.3.6. Benchmarking of Players based in Europe, Established Post 2010 (Peer Group VI)
8.3.7. Benchmarking of Players based in Asia and Rest of the World, Established Pre 2000 (Peer Group VII)
8.3.8. Benchmarking of Players based in Asia and Rest of the World, Established Post 2000 (Peer Group VIII)
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Bioavailability Enhancement: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Type of Partnership and Type of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.4. Analysis by Geography
9.4.1. Analysis by Region
9.4.2. Analysis by Country
9.4.3. Analysis by Type of Partnership and Location of Partner Headquarters
10. PUBLICATION ANALYSIS
11. PATENT ANALYSIS
12. CLINICAL TRIAL ANALYSIS
13. DEMAND ANALYSIS
14. MARKET FORECAST AND OPPURTUNITY ANALYSIS
15. TECHNOLOGY EVALUATION FRAMEWORK
16. CONCLUSION
17. APPENDIX I: LIST OF COMPANIES
18. APPENDIX II: TABULATED DATA
For more information about this report visit https://www.researchandmarkets.com/r/ko8kkp

Yahoo Finance's Anjalee Khemlani explains news of a major biotech merger as Amgen is set to acquire Horizon Therapeutics.
Salesforce Chief Medical Officer Geeta Nayyar speaks with Yahoo Finance health care reporter Anjalee Khemlani about retail health sentiment, the future of health care, and health trends going into 2023.
Colombia's central bank is set to raise its key interest rate this week at its final meeting of the year and will be under pressure for another hike starting in 2023 as inflation expectations keep rising and economic growth remains at potential, a Reuters poll showed on Monday. In the poll, 13 out of 14 analysts said the central bank would raise benchmark interest rates by 100 basis points to 12% this month, while one projected a rise of half a percentage point to 11.5%. If the majority market forecast is met, interest rates could reach levels unseen since December 1999 and would have risen by 1,025 basis points since the beginning of the upward cycle in September last year.
Equities and fixed-income markets have diverged in December, suggesting that investors’ preoccupation with inflation is fading.
Economic weakness plus tighter monetary policy should push inflation below expectations next year, said DoubleLine Capital's Jeffrey Gundlach.
The end of the year is a busy time, but among the long list of things to do should be taking a required minimum distribution – for those who haven’t already done so, are at least 72 years old and have a retirement account. Retirement Tip of the Week: If you haven’t yet taken your required minimum distribution, now is the time to get that sorted to avoid a heavy penalty and a headache.
The finishing line for one of the most turbulent financial market years on record is in sight, but investors must brace for one final wave of volatility this week as the Federal Reserve and three other major central banks set interest rates. The Fed, European Central Bank, Bank of England and the Swiss National Bank are all widely expected to raise rates by 50 basis points each later this week, so the potential market disruption will come from the subsequent press conferences. In Asia, the central bank of The Philippines is expected follow the Fed and reduce the pace of rate hikes to 50 bps from 75 bps at its last meeting, and policymakers in Taiwan are expected to deliver another 12.5 bps hike.
For more than a decade, Chinese developers' debt-fuelled construction boom enriched the country's shadow banks, who were eager to capitalise on the needs of an industry desperate for credit and too risky for traditional lenders. Now, in the wake of a government clampdown on real estate firms' debt binge, that credit demand has collapsed – and so too has the single biggest revenue stream for shadow banks, also known as trust firms. China's shadow banking industry – worth about $3 trillion, roughly the size of Britain's economy – is scrambling for new business, including direct investment in companies, family offices and asset management.
The Dow Jones Industrial Average rose Monday morning, as investors prepared for more inflation data and the Fed meeting this week.
A roundup of recent banking and finance news across Greater Philadelphia: Rapid monetary tightening aimed at reducing inflation will ultimately succeed but at the cost of a global recession next year, according to Vanguard Group’s economic and market outlook for 2023. The report, compiled by a group of the investment management giant’s economists led by Vanguard Chief Economist Joe Davis, said current and expected conditions are similar to those that have signaled past global recessions. Significantly deteriorated financial conditions, increased interest rates, energy concerns, and declining trade volumes indicate the global economy will likely enter a recession in the coming year.
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Virco Manufacturing Corporation (VIRC) delivered earnings and revenue surprises of 2.13% and 3.62%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
New crypto exchange chief points to massive failures under Sam Bankman-Fried ahead of House committee hearing.
Silvergate Capital Corporation (SI) closed the most recent trading day at $21.26, moving -0.79% from the previous trading session.
As investors enter something of a holding pattern ahead of key central bank policy decisions this week, China's markets are on the defensive after yet another indication that the country's economic growth engine is far from purring. It was a reminder to investors that recent optimism surrounding the easing of China's zero-COVID curbs may be a little overdone, and that the path to recovery will be extremely challenging even if economic re-opening is accelerated. China's ambassador to the United States said on Monday that China's COVID-19 policy has always been "dynamic, not rigid," adding that measures will be further relaxed in the near future and international travel to the country will become easier.
Economic growth concerns are buoying bond prices and sending yields lower ahead of this week's inflation data and the Federal Reserve's policy decision. A flip in investor worries from inflation to economic growth has [spurred a bond rally](https://www.wsj.com/articles/slowing-growth-edges-out-inflation-as-top-concern-11670795454?mod=markets_lead_pos3), analysts say. Long-term inflation and interest-rate expectations are also down. + The yield on the benchmark 10-year U.S. Treasury has slid to 3
KeyBanc Capital Markets analyst Alex Markgraff initiated coverage of Coinbase Global Inc. shares with a sector-weight rating Sunday, writing that the company "stands apart for scale, compliance, and trust" in the cryptocurrency ecosystem, though various industrywide pressures keep him from recommending the stock. "Coinbase offers pure-play exposure to the digital-asset ecosystem as an innovative and trusted service provider with a healthy capital position, forward- thinking management team, and
Shares of Micron Technology Inc. and KLA Corp. were each off more than 1% in Monday morning trading after Deutsche Bank analyst Sidney Ho downgraded them to hold from buy. "We are incrementally more cautious on the memory market, as we believe the current downturn will last longer and be more severe than we previously forecasted," Ho wrote in his note to clients about Micron. "On the demand side, weakness in consumer PC/smartphone has now spread to the enterprise side, and even cloud demand is s
Investors sell off the 10-year Treasury note following a weaker-than-average note reopening, pushing its yield above 3.6%.
Michael McCaffrey, the CEO of crypto news outlet The Block, resigned after reports revealed that he received undisclosed multi-million dollar loans from Alameda Research.

source